GSK’s Jemperli (dostarlimab) received an accelerated FDA approval for advanced rectal cancer with a specific genetic signature, extending its earlier indication in endometrial cancer. The action underscores continued regulatory momentum for PD-1 checkpoint blockade strategies that aim to narrow surgery-based treatment pathways.